Plavix eliquis and aspirin

Size: px
Start display at page:

Download "Plavix eliquis and aspirin"

Transcription

1 Plavix eliquis and aspirin The Borg System is 100 % Plavix eliquis and aspirin 273 medications are known to interact with Plavix. Includes amlodipine, aspirin, Aspirin Low Strength ( aspirin ). Eliquis ( Apixaban ) is used for preventing strokes and blood clots in people with atrial fibrillation (a condition characterized by an irregular heartbeat). Learn about Eliquis ( Apixaban Tablets) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications. Learn about Plavix (Clopidogrel Bisulfate) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications. Buy Eliquis online and get competitive Canadian prices on Eliquis delivered to your door from Canada's trusted and certified PricePro Pharmacy. Soll ich Plavix, Efient, Brilique, Aspirin, Pradaxa, Xarelto, Eliquis, Marcoumar oder Sintrom vor meiner geplanten Operation pausieren?. Neue Antikoagulantien (NOAC) 1. Xarelto, Eliquis Orale, direkte Faktor Xa-Inhibitoren. Wirkstoff: Xarelto : Rivaroxaban. Eliquis : Apixaban. Wirkung/Indikation: A total of 384 drugs (1515 brand and generic names) are known to interact with Eliquis ( apixaban ). The classifications below are a general guideline only. Triple therapy with rivaroxaban, apixaban, or dabigatran etexilate combined with ASA and clopidogrel has been tested in patients with ACS to explore whether a prolonged anticoagulation could reduce the.. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. Nov 10, Anticoagulation is the best antithrombotic therapy for the prevention of stroke in patients with atrial fibrillation, and apixaban seems a better option than warfarin by offering a lower risk of systemic embolism, less bleeding, and lower mortality. Combined therapy with aspirin and clopidogrel is less effective. Jul 24, We previously studied the use of apixaban, at doses of 5 to 20 mg daily, in patients who had had recent acute coronary syndromes and who were receiving aspirin or aspirin plus clopidogrel. Treatment with apixaban resulted in dose- related

2 increases in bleeding events and a trend toward fewer ischemic. Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard? Rubboli. The recent development of new, non vitamin K antagonists, direct oral anticoagulants ( NOACs), including dabigatran, apixaban, rivaroxaban, and darexaban, which have more favorable. Nov 21, After BMS implantation triple therapy shall be prescribed for 2-4 weeks followed by OAC plus one antiplatelet alone (aspirin or clopidogrel) whereas there is currently no overall consensus upon. Is a NEW-TRIPLE Therapy with Either Prasugrel/Ticagrelor or Dabigatran/Rivaroxaban/Apixaban an Option?. 110 mg BID, rivaroxaban 15 mg QD and apixaban 2.5 mg BID. *Dual therapy with oral anticoagulation and clopidogrel may be considered in selected patients. ** Aspirin as an alternative to clopidogrel may be considered in patients on dual therapy (i.e. oral anticoagulation plus single antiplatelet). ***Dual therapy with oral. WebMD provides information about interactions between Plavix Oral and antiplatelets-aspirin-100-mg-apixaban. Dec 5, Apixaban, dabigatran and rivaroxaban (formerly known as NOACsa) are non- vitamin K antagonist oral anticoagulants currently listed on the PBS. Apixaban and rivaroxaban are selective inhibitors of factor Xa that block thrombin production, conversion of fibrinogen to fibrin, and thrombus development. Feb 2, The standard antithrombotic agent for patients with coronary artery disease is aspirin; usually a dual therapy with addition of clopidogrel or newer agents is... In conclusion, in patients who require dual or triple therapy, low-dose dabigatran or apixaban might be a good alternative to warfarin due to good. Buy Eliquis online and get competitive Canadian prices on Eliquis delivered to your door from Canada's trusted and certified PricePro Pharmacy. Learn about Eliquis ( Apixaban Tablets) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications. Learn about Plavix (Clopidogrel Bisulfate) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications A total of 384 drugs (1515 brand and generic names) are known to interact with Eliquis ( apixaban ). The classifications below are a general guideline only. Eliquis ( Apixaban ) is used for preventing strokes and blood clots in people with atrial fibrillation (a condition characterized by an irregular heartbeat). 273 medications are known to interact with Plavix. Includes amlodipine, aspirin, Aspirin Low Strength

3 ( aspirin ). Neue Antikoagulantien (NOAC) 1. Xarelto, Eliquis Orale, direkte Faktor Xa-Inhibitoren. Wirkstoff: Xarelto : Rivaroxaban. Eliquis : Apixaban. Wirkung/Indikation: Soll ich Plavix, Efient, Brilique, Aspirin, Pradaxa, Xarelto, Eliquis, Marcoumar oder Sintrom vor meiner geplanten Operation pausieren?. Dec 5, Apixaban, dabigatran and rivaroxaban (formerly known as NOACsa) are non- vitamin K antagonist oral anticoagulants currently listed on the PBS. Apixaban and rivaroxaban are selective inhibitors of factor Xa that block thrombin production, conversion of fibrinogen to fibrin, and thrombus development. Feb 2, The standard antithrombotic agent for patients with coronary artery disease is aspirin; usually a dual therapy with addition of clopidogrel or newer agents is... In conclusion, in patients who require dual or triple therapy, low-dose dabigatran or apixaban might be a good alternative to warfarin due to good. 110 mg BID, rivaroxaban 15 mg QD and apixaban 2.5 mg BID. *Dual therapy with oral anticoagulation and clopidogrel may be considered in selected patients. ** Aspirin as an alternative to clopidogrel may be considered in patients on dual therapy (i.e. oral anticoagulation plus single antiplatelet). ***Dual therapy with oral. Jul 24, We previously studied the use of apixaban, at doses of 5 to 20 mg daily, in patients who had had recent acute coronary syndromes and who were receiving aspirin or aspirin plus clopidogrel. Treatment with apixaban resulted in dose- related increases in bleeding events and a trend toward fewer ischemic. Nov 21, After BMS implantation triple therapy shall be prescribed for 2-4 weeks followed by OAC plus one antiplatelet alone (aspirin or clopidogrel) whereas there is currently no overall consensus upon. Is a NEW-TRIPLE Therapy with Either Prasugrel/Ticagrelor or Dabigatran/Rivaroxaban/Apixaban an Option?. Triple therapy with rivaroxaban, apixaban, or dabigatran etexilate combined with ASA and clopidogrel has been tested in patients with ACS to explore whether a prolonged anticoagulation could reduce the.. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. WebMD provides information about interactions between Plavix Oral and antiplatelets-aspirin-100-mg-apixaban. Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard? Rubboli. The recent development of new, non vitamin K antagonists, direct oral anticoagulants ( NOACs), including dabigatran, apixaban, rivaroxaban, and darexaban, which have more favorable. Nov 10, 2011.

4 Anticoagulation is the best antithrombotic therapy for the prevention of stroke in patients with atrial fibrillation, and apixaban seems a better option than warfarin by offering a lower risk of systemic embolism, less bleeding, and lower mortality. Combined therapy with aspirin and clopidogrel is less effective. Eliquis ( Apixaban ) is used for preventing strokes and blood clots in people with atrial fibrillation (a condition characterized by an irregular heartbeat). Learn about Plavix (Clopidogrel Bisulfate) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications. Learn about Eliquis ( Apixaban Tablets) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications. Buy Eliquis online and get competitive Canadian prices on Eliquis delivered to your door from Canada's trusted and certified PricePro Pharmacy. Soll ich Plavix, Efient, Brilique, Aspirin, Pradaxa, Xarelto, Eliquis, Marcoumar oder Sintrom vor meiner geplanten Operation pausieren?. 273 medications are known to interact with Plavix. Includes amlodipine, aspirin, Aspirin Low Strength ( aspirin ) A total of 384 drugs (1515 brand and generic names) are known to interact with Eliquis ( apixaban ). The classifications below are a general guideline only. Neue Antikoagulantien (NOAC) 1. Xarelto, Eliquis Orale, direkte Faktor Xa-Inhibitoren. Wirkstoff: Xarelto : Rivaroxaban. Eliquis : Apixaban. Wirkung/Indikation: Dec 5, Apixaban, dabigatran and rivaroxaban (formerly known as NOACsa) are nonvitamin K antagonist oral anticoagulants currently listed on the PBS. Apixaban and rivaroxaban are selective inhibitors of factor Xa that block thrombin production, conversion of fibrinogen to fibrin, and thrombus development. 110 mg BID, rivaroxaban 15 mg QD and apixaban 2.5 mg BID. *Dual therapy with oral anticoagulation and clopidogrel may be considered in selected patients. ** Aspirin as an alternative to clopidogrel may be considered in patients on dual therapy (i.e. oral anticoagulation plus single antiplatelet). ***Dual therapy with oral. Nov 21, After BMS implantation triple therapy shall be prescribed for 2-4 weeks followed by OAC plus one antiplatelet alone (aspirin or clopidogrel) whereas there is currently no overall consensus upon. Is a NEW-TRIPLE Therapy with Either Prasugrel/Ticagrelor or Dabigatran/Rivaroxaban/Apixaban an Option?. Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard? Rubboli. The recent development of

5 new, non vitamin K antagonists, direct oral anticoagulants ( NOACs), including dabigatran, apixaban, rivaroxaban, and darexaban, which have more favorable. Triple therapy with rivaroxaban, apixaban, or dabigatran etexilate combined with ASA and clopidogrel has been tested in patients with ACS to explore whether a prolonged anticoagulation could reduce the.. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. Jul 24, We previously studied the use of apixaban, at doses of 5 to 20 mg daily, in patients who had had recent acute coronary syndromes and who were receiving aspirin or aspirin plus clopidogrel. Treatment with apixaban resulted in dose- related increases in bleeding events and a trend toward fewer ischemic. Nov 10, Anticoagulation is the best antithrombotic therapy for the prevention of stroke in patients with atrial fibrillation, and apixaban seems a better option than warfarin by offering a lower risk of systemic embolism, less bleeding, and lower mortality. Combined therapy with aspirin and clopidogrel is less effective. Feb 2, The standard antithrombotic agent for patients with coronary artery disease is aspirin; usually a dual therapy with addition of clopidogrel or newer agents is... In conclusion, in patients who require dual or triple therapy, low-dose dabigatran or apixaban might be a good alternative to warfarin due to good. WebMD provides information about interactions between Plavix Oral and antiplatelets-aspirin-100-mg-apixaban. Contact Information Telephone or BORG (2674) FAX Postal address Minnetonka Industrial Rd. Minnetonka, MN Electronic mail General Information: Colt lawman iii holster miya bhai ki dp whatsapp Sitemap Thursday, July 29, 1999 This Site Has Been Visited Times.

6

Eliquis and plavix combination therapy

Eliquis and plavix combination therapy Eliquis and plavix combination therapy ELIQUIS Dosing for Patients With NVAF. patients treated with aspirin or the combination of bleeding or completion of a course of therapy,. 9-11-2011 Thrombosis is

More information

Eliquis effect on inr prolongation 2017

Eliquis effect on inr prolongation 2017 Eliquis effect on inr prolongation 2017 The Borg System is 100 % Eliquis effect on inr prolongation 2017 Dec 17, 2016. Clin Chem Lab Med 2017; 55(8): e178 e180. Letter to the Editor. Tuukka A. Helin. prolongs

More information

When and how to combine antiplatelet agents and anticoagulant?

When and how to combine antiplatelet agents and anticoagulant? When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation

More information

Acetaminophen interaction with eliquis

Acetaminophen interaction with eliquis Acetaminophen interaction with eliquis The Borg System is 100 % Acetaminophen interaction with eliquis Apr 21, 2015. Common household painkillers may double the risk of bleeding associated with Eliquis..

More information

Xarelto and plavix taken together.

Xarelto and plavix taken together. Toggle navigation Xarelto and plavix taken together. Integrilin (eptifibatide) helps to prevent platelets in your blood from sticking together and forming a blood clot. An unwanted blood clot can occur

More information

TRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust

TRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current

More information

Global Anticoagulants Market: Size, Trends & Forecasts ( ) April 2017

Global Anticoagulants Market: Size, Trends & Forecasts ( ) April 2017 Global Anticoagulants Market: Size, Trends & Forecasts (2017-2021) April 2017 Global Anticoagulants Market Scope of the Report The report entitled Global Anticoagulants Market: Size, Trends & Forecasts

More information

Lovenox to xarelto The Borg System is 100 % Retrievable & Reusable Lovenox to xarelto

Lovenox to xarelto The Borg System is 100 % Retrievable & Reusable Lovenox to xarelto Lovenox to xarelto The Borg System is 100 % Lovenox to xarelto Background: I got a DVT in my left calf after my fifth knee surgery. I'm a 32yo healthy, competitive athlete and have never had any healthy

More information

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Antiplatelets and Anticoagulants Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Mechanism 2 http://www.medicinehack.com/2011/07/virchows-triad.html Mechanism 3 http://drtedwilliams.net/kb/index.php?pagename=coagulation%20cascade

More information

Plavix duration of effect

Plavix duration of effect Plavix duration of effect The Borg System is 100 % Plavix duration of effect Jan 20, 2015. If you have had stent placement after balloon angioplasty for coronary artery disease you will be placed on medications

More information

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet

More information

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients

More information

Drug Class Review Newer Oral Anticoagulant Drugs

Drug Class Review Newer Oral Anticoagulant Drugs Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different

More information

Asif Serajian DO FACC FSCAI

Asif Serajian DO FACC FSCAI Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac

More information

Patient with high risk for bleeding

Patient with high risk for bleeding Will Apixaban change practice in atrial fibrillation Luncheon Satellite Sponsored by Pfizer Patient with high risk for bleeding Prof. Amos Katz M.D August 2012: patient background 67-year-old woman History

More information

INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA

INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular

More information

Afib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS

Afib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial

More information

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation

More information

DIRECT ORAL ANTICOAGULANTS

DIRECT ORAL ANTICOAGULANTS 2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral

More information

GLORIA -AF REGISTRY PROGRAMME

GLORIA -AF REGISTRY PROGRAMME GLORIA -AF REGISTRY PROGRAMME EXECUTIVE SUMMARY The approval of novel oral anticoagulants has changed prescribing patterns for stroke prevention in atrial fibrillation (AF) worldwide. 1 There is a need

More information

New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital

New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,

More information

Stable CAD, Elective Stenting and AFib

Stable CAD, Elective Stenting and AFib Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School

More information

ESC Congress 2012, Munich

ESC Congress 2012, Munich ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,

More information

Prostate Biopsy Alerts

Prostate Biopsy Alerts Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table

More information

Anti-thromboticthrombotic drugs

Anti-thromboticthrombotic drugs Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF

More information

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe

More information

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Which drug do you prefer for stable CAD? - P2Y12 inhibitor Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,

More information

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations

More information

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations

More information

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to

More information

Aspirin versus pradaxa

Aspirin versus pradaxa Search Search Aspirin versus pradaxa 14-12-2012 Dabigatran (Pradaxa): Good news on safety but caution still warranted. the risk of bleeding versus the risk. (Aspirin and other inhibitors of. 15-12-2008

More information

Dual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015

Dual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015 Dual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015 Wesam A Alhejily MD FRCPC FACP FACC FSCAI Assistant Professor of Medicine Chief Of Adult Cardiology Consultant

More information

Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation

Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist

More information

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma

More information

Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA

Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran:

More information

ADVANCES IN ANTICOAGULATION

ADVANCES IN ANTICOAGULATION ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants

More information

A PATIENT S GUIDE TO THE LEFT ATRIAL APPENDAGE CLOSURE. Reducing the risk of stroke in atrial fibrillation

A PATIENT S GUIDE TO THE LEFT ATRIAL APPENDAGE CLOSURE. Reducing the risk of stroke in atrial fibrillation A PATIENT S GUIDE TO THE LEFT ATRIAL APPENDAGE CLOSURE Reducing the risk of stroke in atrial fibrillation TABLE OF CONTENTS IMPORTANT Please Note: Information provided by Boston Scientific Corporation

More information

STROKE PREVENTION in non-valvular AF: NOACs (or DOACs?) or Vitamin K antagonists?

STROKE PREVENTION in non-valvular AF: NOACs (or DOACs?) or Vitamin K antagonists? STROKE PREVENTION in non-valvular AF: NOACs (or DOACs?) or Vitamin K antagonists? Prof. Dr. Alain Dupont Head, Clinical Pharmacology and Pharmacotherapy UZ Brussel/VUB Stroke and Atrial FibrillaDon 2 29/03/17

More information

Anticoagulation Task Force

Anticoagulation Task Force Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration

More information

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting

More information

Lessons from recent antithrombotic studies and trials in atrial fibrillation

Lessons from recent antithrombotic studies and trials in atrial fibrillation Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin

More information

Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?

Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013

More information

Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES

Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,

More information

STROKE PREVENTION 5/11/2015. Stroke Incidence by Age. Cardiogenic Embolism is the most common cause of stroke

STROKE PREVENTION 5/11/2015. Stroke Incidence by Age. Cardiogenic Embolism is the most common cause of stroke (%) (%) 5/11/15 STROKE PREVENTION Stroke Incidence by Age T H E G E N E R A L P R A C T I C E E D U C A T I O N D A Y U N I V E R S I T Y O F Q U E E N S L A N D 3 1 O C T O B E R 2 1 5 A S S O C I A T

More information

KCS Congress: Impact through collaboration

KCS Congress: Impact through collaboration Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact

More information

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,

More information

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to

More information

Peer Review Report #2. Novel oral anticoagulants. (1) Does the application adequately address the issue of the public health need for the medicine?

Peer Review Report #2. Novel oral anticoagulants. (1) Does the application adequately address the issue of the public health need for the medicine? 20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report #2 vel oral anticoagulants (1) Does the application adequately address the issue of the public health need for the

More information

THROMBOTIC DISORDERS: The Final Frontier

THROMBOTIC DISORDERS: The Final Frontier THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.

More information

Treatment with Apixaban Eliquis

Treatment with Apixaban Eliquis Treatment with Apixaban Eliquis Anticoagulation Clinic 416-530-6000 ext 3477 This handout explains the medicine rivaroxaban, a drug that helps prevent blood clots. What is apixaban? Apixaban (brand name

More information

New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy

New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest

More information

Professional Practice Minutes December 7, 2016

Professional Practice Minutes December 7, 2016 Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon

More information

NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna

NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable

More information

Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:

Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%

More information

Nanik Hatsakorzian Pharm.D/MPH

Nanik Hatsakorzian Pharm.D/MPH Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome

More information

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA

More information

Guiding Secondary Stroke Prevention through Evaluation of Ischemic Stroke Etiology

Guiding Secondary Stroke Prevention through Evaluation of Ischemic Stroke Etiology Guiding Secondary Stroke Prevention through Evaluation of Ischemic Stroke Etiology Ann M. Leonhardt Caprio, MS, RN, ANP-BC Program Coordinator Comprehensive Stroke Center, Strong Memorial Hospital Clinical

More information

Novel Anticoagulants: Emerging Evidence

Novel Anticoagulants: Emerging Evidence 18/10/2016 Topics: Novel Anticoagulants: Emerging Evidence Dr Matthew Swale Electrophysiologist Genesis Care NOAC Novel Oral Anti Coagulant Now Non-Vit K Oral Anti Coagulant DOAC Direct Oral Anti Coagulant

More information

Updates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy

Updates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest

More information

Anticoagulants: Agents, Pharmacology and Reversal

Anticoagulants: Agents, Pharmacology and Reversal Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University

More information

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address

More information

Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine

Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole

More information

ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION

ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most

More information

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process

More information

Clinical Practice Guideline for Anticoagulation Management

Clinical Practice Guideline for Anticoagulation Management Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.

More information

Anticoagulatie en de oudere patiënt: Terughoudenheid gerechtvaardigd of niet?

Anticoagulatie en de oudere patiënt: Terughoudenheid gerechtvaardigd of niet? Anticoagulatie en de oudere patiënt: Terughoudenheid gerechtvaardigd of niet? 16/06/2018 apr. Julie Hias Satellite symposium supported by the Alliance BMS/Pfizer 432BE18PR03459/ 180570 (Date of Preparation:

More information

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate

More information

Treatment with Rivaroxaban Xarelto

Treatment with Rivaroxaban Xarelto Treatment with Rivaroxaban Xarelto Anticoagulation Clinic This handout explains the medicine rivaroxaban, a drug that helps prevent blood clots. What is rivaroxaban? Rivaroxaban (brand name Xarelto) is

More information

Study period Total sample size (% women) 899 (37.7%) Warfarin Aspirin

Study period Total sample size (% women) 899 (37.7%) Warfarin Aspirin Table S2 Sex- specific differences in oral anticoagulant prescription for stroke prevention in AF Total sample size (% women) Anticoagulant(s) studied Gage (2000) 1 Missouri, USA Discharged during 597

More information

Change from lovenox to pradaxa

Change from lovenox to pradaxa P ford residence southampton, ny Change from lovenox to pradaxa 14-11-2017 We wanted to put out a friendly reminder that the Ask 3 Teach 3 (A3T3) initiative is indeed full swing. This is an multidisciplinary

More information

Atrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto

Atrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto

More information

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban

More information

Secondary Stroke Prevention: A Precautionary Tale

Secondary Stroke Prevention: A Precautionary Tale Secondary Stroke Prevention: A Precautionary Tale Kirsten George-Phillips, BSP Clinical Practice Leader, AHS Clinical Pharmacist, AHS Owen Stroke Prevention Clinic Learning Objectives! Examine literature

More information

Anticoagulation in Atrial Fibrillation Patient information

Anticoagulation in Atrial Fibrillation Patient information Anticoagulation in Atrial Fibrillation Patient information Introduction This leaflet will help you understand your new medicine. Your new medicine is commonly known as a blood thinner because that is what

More information

Atrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie

Atrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow

More information

Volume 7; Number 16 October 2013

Volume 7; Number 16 October 2013 Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire

More information

Antithrombotics in Stroke management

Antithrombotics in Stroke management Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,

More information

ADC Slides for Presentation 02/10/2017

ADC Slides for Presentation 02/10/2017 ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine

More information

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor

More information

PCI in Patients with AF Optimizing Oral Anticoagulation Regimen

PCI in Patients with AF Optimizing Oral Anticoagulation Regimen PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and

More information

David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy

David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy stewardw@etsu.edu At the conclusion of this program, the audience should

More information

Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital

Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital Complicated issues in GI bleeding; Survey results from internists Optimal resuscitation

More information

Old and New Anticoagulants For Stroke Prevention Benefits and Risks

Old and New Anticoagulants For Stroke Prevention Benefits and Risks Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry

More information

Pradaxa (dabigatran)

Pradaxa (dabigatran) Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa

More information

Individual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD

Individual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant

More information

Clinical issues which drug for which patient

Clinical issues which drug for which patient Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest

More information

Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University

Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude

More information

Antithrombotic Efficacy and Safety of Dabigatran Etexilate

Antithrombotic Efficacy and Safety of Dabigatran Etexilate 130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of

More information

NOACS/DOACS*: COAGULATION TESTS

NOACS/DOACS*: COAGULATION TESTS NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international

More information

The Age of the Novel Anticoagulants. Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology

The Age of the Novel Anticoagulants. Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology The Age of the Novel Anticoagulants Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology Disclosures Speaker bureau for the Bristol-Myers Squibb and Pfizer alliance for Eliquis Direct

More information

Acetaminophen interaction with eliquis

Acetaminophen interaction with eliquis Acetaminophen interaction with eliquis Acetaminophen Oral on WebMD safety, interactions, pictures, warnings and user ratings. 23-2-2018 View drug interactions between acetaminophen and Eliquis. These medicines

More information

Appendix C Factors to consider when choosing between anticoagulant options and FAQs

Appendix C Factors to consider when choosing between anticoagulant options and FAQs Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened

More information

Blood-thinning medication after stroke

Blood-thinning medication after stroke Call the Stroke Helpline: 0303 3033 100 or email: info@stroke.org.uk Blood-thinning medication after stroke Blood-thinning medicines are drugs that help to prevent clots forming in your blood. They are

More information

Drug Use Criteria: Direct Oral Anticoagulants

Drug Use Criteria: Direct Oral Anticoagulants Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed

More information

Oral Anticoagulation Drug Class Prior Authorization Protocol

Oral Anticoagulation Drug Class Prior Authorization Protocol Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Technician Training Tutorial: Dispensing Oral Blood Thinners

Technician Training Tutorial: Dispensing Oral Blood Thinners (Page 1 of 5) Technician Training Tutorial: Dispensing Oral Blood Thinners Warfarin (Coumadin, Jantoven-U.S., others) is an oral anticoagulant blood thinner used to help prevent blood clots that can lead

More information

Medicines for stroke prevention in atrial fibrillation. Choosing the right one for you

Medicines for stroke prevention in atrial fibrillation. Choosing the right one for you Medicines for stroke prevention in atrial fibrillation Choosing the right one for you Atrial fibrillation (AF) is a condition that affects the heart, causing it to beat irregularly and too fast. When this

More information

Chapter 1 Introduction

Chapter 1 Introduction Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep

More information

When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD

When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven

More information

325 mg aspirin and plavix

325 mg aspirin and plavix 325 mg aspirin and plavix 12-3-2006 Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for. Compare Aspirin

More information